Does Tafamidis Meglumine Interact with Rosuvastatin?
CDI records a moderate classification for Tafamidis Meglumine and Rosuvastatin. The stored summary is: Tafamidis inhibits BCRP, increasing rosuvastatin exposure and toxicity risk. Monitor for toxicities and adjust dosage if needed. The mechanism involves bcrp inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Rosuvastatin Class
- HMG-CoA Reductase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
BCRP inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Tafamidis Meglumine and your doctor is considering prescribing Rosuvastatin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider